[1] Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nature reviews Molecular cell biology. 2018 Nov 20:1.
[2] Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. The Journal of clinical investigation. 2009 Jun 1;119(6):1420-8.
[3] Gyamfi J, Lee YH, Eom M, Choi J. Interleukin-6/STAT3 signalling regulates adipocyte induced epithelial-mesenchymal transition in breast cancer cells. Scientific reports. 2018 Jun 11;8(1):8859.
[4] Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature reviews Clinical oncology. 2017 Oct;14(10):611.
[5] Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016 Jun 30;166(1):21-45.
[6] Stemmler MP, Eccles RL, Brabletz S, Brabletz T. Non-redundant functions of EMT transcription factors. Nature cell biology. 2019 Jan;21(1):102.
[7] Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cells. EMBO reports. 2008 Jun 1;9(6):582-9.
[8] Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature cell biology. 2008 May;10(5):593.
[9] Kim NH, Kim HS, Li XY, Lee I, Choi HS, Kang SE, Cha SY, Ryu JK, Yoon D, Fearon ER, Rowe RG. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition. J Cell biol. 2011 Oct 31;195(3):417-33.
[10] Moradi S, Asgari S, Baharvand H. Concise review: harmonies played by microRNAs in cell fate reprogramming. Stem Cells. 2014 Jan;32(1):3-15.
[11] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell. 2004 Jan 23;116(2):281-97.
[12] Zaravinos A. The regulatory role of microRNAs in EMT and cancer. Journal of oncology. 2015;2015.
[13] Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Molecular cell. 2007 Jul 6;27(1):91-105.
[14] Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic acids research. 2018 Nov 13;47(D1):D155-62.
[15] Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Research. 2017 Dec;19(1):133.
[16] Behbahani GD, Ghahhari NM, Javidi MA, Molan AF, Feizi N, Babashah S. MicroRNA-mediated post-transcriptional regulation of epithelial to mesenchymal transition in cancer. Pathology & Oncology Research. 2017 Jan 1;23(1):1-2.
[17] Zare M, Bastami M, Solali S, Alivand MR. Aberrant miRNA promoter methylation and EMT‐involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. Journal of cellular physiology. 2018 May;233(5):3729-44.
[18] Chen H, Liu H, Zou H, Chen R, Dou Y, Sheng S, Dai S, Ai J, Melson J, Kittles RA, Pirooznia M. Evaluation of plasma miR-21 and miR-152 as diagnostic biomarkers for common types of human cancers. Journal of cancer. 2016;7(5):490.
[19] Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacology & therapeutics. 2017 Apr 1;172:34-49.
[20] Zhao XG, Hu JY, Tang J, Yi W, Zhang MY, Deng R, Mai SJ, Weng NQ, Wang RQ, Liu J, Zhang HZ. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell death & disease. 2019 Jun 17;10(7):479.
[21] Riffo-Campos ÁL, Riquelme I, Brebi-Mieville P. Tools for sequence-based miRNA target prediction: what to choose?. International journal of molecular sciences. 2016 Dec;17(12):1987.
[22] Sticht C, De La Torre C, Parveen A, Gretz N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS One. 2018 Oct 18;13(10):e0206239.
[23] Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L, Congdon CB. Common features of microRNA target prediction tools. Frontiers in genetics. 2014 Feb 18;5:23.
[24] Vlachos IS, Paraskevopoulou MD, Karagkouni D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL, Maniou S, Karathanou K, Kalfakakou D, Fevgas A. DIANA-TarBase v7. 0: indexing more than half a million experimentally supported miRNA: mRNA interactions. Nucleic acids research. 2014 Nov 21;43(D1):D153-9.
[25] Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T, Hatzigeorgiou AG. DIANA-microT web server v5. 0: service integration into miRNA functional analysis workflows. Nucleic acids research. 2013 May 16;41(W1):W169-73.
[26] Lu TP, Lee CY, Tsai MH, Chiu YC, Hsiao CK, Lai LC, Chuang EY. miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PloS one. 2012 Aug 1;7(8):e42390.
[27] Xiong Y, Wang Y, Wang L, Huang Y, Xu Y, Xu L, Guo Y, Lu J, Li X, Zhu M, Qian H. MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells. Journal of Cancer. 2018;9(12):2147.
[28] Ma S, Jia W, Ni S. miR-199a-5p inhibits the progression of papillary thyroid carcinoma by targeting SNAI1. Biochemical and biophysical research communications. 2018 Feb 26;497(1):181-6.
[29] Chen J, Shin VY, Siu MT, Ho JC, Cheuk I, Kwong A. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC cancer. 2016 Dec;16(1):887.
[30] Su-Jin Y, Su-Yu Y, Dan-Dan W, Chen X, Hong-Yu S, Xiao-Hui Z, Shan-Liang Z, Jin-Hai T, Zhao JH. The miR-30 family: Versatile players in breast cancer. Tumor Biology. 2017 Mar 1;39(3).
[31] Liu GH, Liu YH, Yang Z, Zhu AL, Zhao CL. MicroRNA-524 5p suppresses the growth and invasive abilities of gastric cancer cells. Oncology letters. 2016 Mar 1;11(3):1926-32.
[32] Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumor Biology. 2014 Aug 1;35(8):7335-42.
[33] Nguyen PN, Choo KB, Huang CJ, Sugii S, Cheong SK, Kamarul T. miR-524-5p of the primate-specific C19MC miRNA cluster targets TP53IPN1-and EMT-associated genes to regulate cellular reprogramming. Stem cell research & therapy. 2017 Dec;8(1):214.
[34] Tsukerman P, Yamin R, Seidel E, Khawaled S, Schmiedel D, Bar-Mag T, Mandelboim O. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget. 2014 Dec;5(23):12141.
[35] Ye YP, Wu P, Gu CC, Deng DL, Jiao HL, Li TT, Wang SY, Wang YX, Xiao ZY, Wei WT, Chen YR. miR-450b-5p induced by oncogenic KRAS is required for colorectal cancer progression. Oncotarget. 2016 Sep 20;7(38):61312.
[36] Shi Y, Yang Z, Zhang T, Shen L, Li Y, Ding S. SIRT1-targeted miR-543 autophagy inhibition and epithelial–mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer. Cell death & disease. 2019 Aug 19;10(9):1-4.
[37] Du Y, Zhu HC, Liu XH, Wang L, Ning JZ, Xiao CC. MiR-543 promotes proliferation and epithelial-mesenchymal transition in prostate cancer via targeting RKIP. Cellular Physiology and Biochemistry. 2017;41(3):1135-46.
[38] Zhou Y, Xu Q, Shang J, Lu L, Chen G. Crocin inhibits the migration, invasion, and epithelial‐mesenchymal transition of gastric cancer cells via miR‐320/KLF5/HIF‐1α signaling. Journal of cellular physiology. 2019 Mar 9.
[39] Lv QL, Du H, Liu YL, Huang YT, Wang GH, Zhang X, Chen SH, Zhou HH. Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. Oncology reports. 2017 Aug 1;38(2):959-66.
[40] Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC, Ma R. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Gene. 2017 Jul 1;619:10-20.
[41] Ogawa H, Wu X, Kawamoto K, Nishida N, Konno M, Koseki J, Matsui H, Noguchi K, Gotoh N, Yamamoto T, Miyata K. MicroRNAs induce epigenetic reprogramming and suppress malignant phenotypes of human colon cancer cells. PLoS One. 2015 May 13;10(5):e0127119.
[42] Liang YJ, Wang QY, Zhou CX, Yin QQ, He M, Yu XT, Cao DX, Chen GQ, He JR, Zhao Q. MiR-124 targets Slug to regulate epithelial–mesenchymal transition and metastasis of breast cancer. Carcinogenesis. 2012 Dec 17;34(3):713-22.